Rescue of combination therapy failures using infliximab, while maintaining the combination or monotherapy with methotrexate: Results of an open trial

Rheumatology

Volumn 41, Issue 10, 2002, Pages 1109-1112

  Ferraccioli, G F ^a   Assaloni, R ^a   Di Poi, E ^a   Gremese, E ^a   De Marchi, G ^a   Fabris, M ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

CsA; Infliximab; MTX; Rapidly aggressive progressive rheumatoid arthritis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOLIPIN ANTIBODY; CYCLOSPORIN A; HEPARIN; IMMUNOGLOBULIN M; INFLIXIMAB; METHOTREXATE;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART MUSCLE ISCHEMIA; HUMAN; MALE; NEPHROTOXICITY; PHARYNGITIS; PRIORITY JOURNAL; RECURRENT DISEASE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; STATISTICAL ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TIME; TREATMENT FAILURE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 0036798294     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Pincus T. Aggressive treatment of early RA to prevent joint damage. Bull Rheum Dis 1999;47:2-7.
2. Kremer JM, Lee JK. A long term prospective study of the use of MTX in rheumatoid arthritis. Update after a mean of 53 months. Arthritis Rheum 1988;31:577-84.
3. Reykdal S, Steinsson K, Sigurjonsson K, Brekkan A. Methotrexate treatment of rheumatoid arthritis: Update after a mean of 53 months. Scand J Rheumatol 1989; 18:221-6.
4. Rau R, Herborn G, Karger T, Werdier D. Retardation of radiologic progression in rheumatoid arthritis with methotrexate therapy: a controlled study. Arthritis Rheum 1991;34:1236-44.
5. Fries JF. Reevaluating the therapeutic approach to rheumatoid arthritis: the 'sawtooth' strategy. J Rheumatol 1990;17(Suppl. 22):12-5.
6. Ferraccioli GF, Valentini G, Valesini G, Bombardieri S. Reconstructing the pyramid in rheumatoid arthritis. An urgent need. Clin Exp Rheumatol 2001;19:621-4.
7. Mottonen T, Hannonen P, Leirisalo-Repo M et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomized trial. FIN-RACo trial group. Lancet 1999;353:1568-73.
8. Strand V, Cohen S, Schiff M et al. for the Leflunomide Rheumatoid Arthritis Investigators Group. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Int Med 1999; 159:2542-50.
9. Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptors: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340:253-9.
10. Bathon JM, Martin RW, Fleishmann RM et al. comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343:1586-93.
11. Lipsky PE. Van der Heijde DMFM, St Clair EW et al. for the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
12. Prevoo MLL, Van Gestel AM, Van't Hof MA, Van Rijswijk MH, Van de Putte LBA, Van Riel PLCM. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 1996;35:1101-5.
13. Ferraccioli GF, Mecchia F, Di Poi E, Fabris M. Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann Rheum Dis 2002;61:358-61.
14. Williams R. Healthy carriage of Staphylococcus aureus: its prevalence and importance. Bacteriol Rev 1963;27:56-71.
15. Stegeman CA, Tervaert JW, Sluiter WJ, Manson WL, De Jong PE, Kallenberg CG. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener's granulomatosis. Ann Intern Med 1994; 120:12-7.